In patients with HBeAg-positive CHB, 5 years of antiviral treatment with ETV demonstrated an accumulative probability to develop the virological response of 99%, and HBeAg loss of 53%, but only 1.4% of the included patients achieved the HBsAg loss.34 Similarly, HBeAg-positive patients treated 10 years with TDF lost the HBeAg in 52% but the HBsAg only in 4.9%.35